Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04433169

All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck — Aplus  

Adenoid Cystic Carcinoma of the Head and Neck Clinical Trial

Official title:
A Prospective, Open-label, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of All-trans Retinoic Acid (ATRA) in the Treatment of Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck

Clinical Trial Summary

This is a prospective, open-label, randomized controlled clinical intervention study to evaluate the efficacy and safety of all-trans retinoic acid (ATRA) in treating patients with recurrent metastatic adenoid cystic carcinoma of the head and neck.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04433169
Study type Interventional
Source Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Contact Guopei Zhu, M.D
Phone 021-23271699
Email antica@gmail.com
Status Recruiting
Phase Phase 2
Start date June 3, 2020
Completion date June 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05930951 - Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck Phase 1